Mylan Pharmaceuticals faces another recall on insulin injection pens
2022-07-06
并购
Viatris Pharmaceuticals’ Mylan unit is facing yet another recall on a batch of its insulin.
On Tuesday, Viatris — which was formed out of a $12 billion merger between Mylan and Pfizer’s Upjohn unit back in 2020 — announced that Mylan Pharmaceuticals is voluntarily recalling one batch of insulin glargine injection, 3 mL prefilled pens due to potential missing labels.
The batch — numbered BF21002895 — is not the branded Semglee pen, but rather the unbranded insulin pens that are packaged in cartons of five. This batch is being recalled due to the potential for the label to be missing on some pens, and the FDA has been made aware of the recall, the company said.
For patients receiving treatment with more than one type of insulin, a missing label on these pens could lead to a mix-up of products or strengths, which can result in less optimal glycemic control or other serious complications, the company added.
However, no adverse events related to this recall have been reported. The batch was manufactured by Biocon and was distributed by Mylan in the US between April 4 and May 5.
This isn’t the first recall for one of Mylan’s insulin products this year.
In January
, a batch of its Semglee branded insulin pens was released without labels, the FDA said.
Then in April
, another recall was issued, as the company announced another batch of insulin, this time glargine for injection cartridge form, had to be recalled for the same labeling issue. This batch was also made by Biocon and distributed by Mylan.
Consumers with questions about the recall can contact Viatris customer relations by phone at 1-800-796-9526 or by email at customer.service@viatris.com
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
-靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。